Pacira Biosciences Inc (PCRX): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Pacira Biosciences Inc (PCRX) following the 2026 Q1 hedge fund 13F filings?

As of today, PCRX has moved +0.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -3.9%. Since the quarter end (March 31, 2026), PCRX gained +0.2% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Pacira Biosciences Inc (PCRX)

236 + Investors. Track Smart Money conviction in PCRX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — PCRX

Based on 237 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their PCRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

📊

High ownership — 87% of 3.0Y peak

87% of all-time peak

237 funds currently hold this stock — 87% of the 3.0-year high of 273 funds (reached 2024 Q2). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.

〰️

Stable — ownership unchanged year-over-year

fund count last 6Q

The number of hedge funds holding PCRX is almost the same as a year ago (+6 funds, +3% change). No significant rush to buy or sell — institutional backing is holding steady.

🟠

More sellers than buyers — 48% buying

121 buying129 selling

Last quarter: 129 funds reduced or exited vs 121 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

⚠️

Fewer new buyers each quarter (-20 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 31 → 37 → 48 → 28. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

65% of holders stayed for 2+ years

■ 65% conviction (2yr+) ■ 17% medium ■ 18% new

153 out of 237 hedge funds have held PCRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

📈

Growing discovery — still being found

36 → 31 → 37 → 48 → 28 new funds/Q

New funds entering each quarter: 31 → 37 → 48 → 28. A growing number of institutions are discovering PCRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 67% veterans vs 24% newcomers

■ 67% veterans ■ 9% 1-2yr ■ 24% new

Entry-cohort mix of 239 holders: 160 (67%) are 2+ year veterans, 22 entered 1–2 years ago, and 57 (24%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 42% AUM from top-100 funds

42% from top-100 AUM funds

49 of 237 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in PCRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.0

out of 10

Low Exit Risk

Exit risk score 3.0/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	236	256	-7.81%
13F Shares	43M	47M	-8.26%
Total Value	$953M	$1.21B	-21.47%
New Positions	27	48	-21
Increased Positions	90	89	+1
Closed Positions	47	27	+20
Reduced Positions	82	89	-7
Total Calls	1	3	-66.67%
Total Puts	1	1	-
PUT/CALL Ratio	1.0	0.33	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

236

256

-7.81%

13F Shares

43M

47M

-8.26%

Total Value

$953M

$1.21B

-21.47%

New Positions

-21

Increased Positions

Closed Positions

+20

Reduced Positions

-7

Total Calls

-66.67%

Total Puts

PUT/CALL Ratio

1.0

0.33

Neutral

Institutional Holders (2026 Q1)

236 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PCRX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 PCRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Doma Perpetual Capital Management LLC	16.86%	2,777,794	$62.8M
2	Gagnon Advisors, LLC	5.86%	352,637	$8.0M
3	Gagnon Securities LLC	3.22%	617,510	$14.0M
4	Bridge City Capital, LLC	2.52%	402,765	$9.1M
5	Lion Point Capital, LP	1.82%	13,500	$305K
6	Easterly Investment Partners LLC	0.59%	334,854	$7.7M
7	Phocas Financial Corp.	0.41%	114,413	$2.6M
8	Three Seasons Wealth, LLC	0.38%	43,835	$991K
9	Milestone Asset Management, LLC	0.25%	60,058	$1.4M
10	Hillsdale Investment Management Inc.	0.20%	331,300	$7.5M
11	Bridgeway Capital Management, LLC	0.19%	411,373	$9.3M
12	PDT Partners, LLC	0.18%	132,368	$3.0M
13	EntryPoint Capital, LLC	0.14%	21,268	$481K
14	Hennion & Walsh Asset Management, Inc.	0.12%	155,396	$3.5M
15	Impax Asset Management Group plc	0.12%	750,027	$17.0M
16	Rice Hall James & Associates, LLC	0.11%	88,844	$2.0M
17	Prelude Capital Management, LLC	0.09%	50,735	$1.1M
18	Legato Capital Management LLC	0.08%	39,007	$882K
19	Virtus Advisers, LLC	0.07%	6,765	$153K
20	Renaissance Technologies LLC	0.06%	1,825,501	$41.3M
21	J. Goldman & Co LP	0.06%	97,772	$2.2M
22	Martingale Asset Management L P	0.06%	108,823	$2.5M
23	Caitlin John, LLC	0.06%	4,384	$99K
24	Greenwood Capital Associates LLC	0.06%	22,795	$515K
25	Inspire Investing, LLC	0.04%	22,574	$510K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Pacira Biosciences Inc (PCRX)

What does the Smart Money Trend signal show for PCRX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their PCRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for PCRX?

More sellers than buyers — 48% buying: Last quarter: 129 funds reduced or exited vs 121 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for PCRX holders?

Elite ownership — 42% AUM from top-100 funds: 49 of 237 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in PCRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held PCRX?

65% of holders stayed for 2+ years: 153 out of 237 hedge funds have held PCRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Pacira Biosciences Inc (PCRX) following the 2026 Q1 hedge fund 13F filings?

As of today, PCRX has moved +0.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -3.9%. Since the quarter end (March 31, 2026), PCRX has gained +0.2% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Pacira Biosciences Inc (PCRX)

Smart Money Signals — PCRX

Selling streak — 1 quarter in a row

High ownership — 87% of 3.0Y peak

Stable — ownership unchanged year-over-year

More sellers than buyers — 48% buying

Fewer new buyers each quarter (-20 vs last Q)

65% of holders stayed for 2+ years

Growing discovery — still being found

Veteran-anchored — 67% veterans vs 24% newcomers

Elite ownership — 42% AUM from top-100 funds

Institutional Sentiment Summary — PCRX

Hedge Fund Ownership: PCRX

Market Analysis: PCRX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: PCRX

Is It Too Late to Buy Pacira Biosciences Inc (PCRX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: PCRX

Statistics: PCRX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Pacira Biosciences Inc (PCRX)

Welcome to 13Foresight!